39th AGM proceedings: re-appointment of two Whole-time Directors and one director retiring by rotation

39th AGM held on September 30, 2026 via video conferencing.

Wed 30 Sep 2026

AGM Date

September 30, 2026

Members Present

67 members (1 promoter, 66 public)

Mr. Sri Kalyan Kompella Term

Whole-time Director & CFO, November 03, 2026 to November 02, 2031 (5 years)

Dr. Sankaranarayanan Alangudi Term

Whole-time Director, January 06, 2027 to January 05, 2032 (5 years)

Voting Results Date

On or before October 03, 2026

What was shared

Vivo Bio Tech submitted the proceedings of its 39th Annual General Meeting, held on Wednesday, September 30, 2026 at 3:00 p.m. through video conferencing, along with details of the director re-appointments placed before members.

Attendance

• Promoter members present: 01
• Public members present: 66
• Total members present: 67
• All directors were present, including the chairpersons of the Audit, Nomination & Remuneration and Stakeholders Relationship Committees.

Items of business transacted

• Adoption of the audited standalone and consolidated financial statements for the financial year ended March 31, 2026, with the Auditors' Report and Board's Report.
• Appointment of a director in place of Mr. Kalyan Ram Mangipudi (DIN: 02012580), who retired by rotation and offered himself for re-appointment.
• Re-appointment of Mr. Sri Kalyan Kompella (DIN: 03137506) as Whole-time Director.
• Re-appointment of Dr. Sankaranarayanan Alangudi (DIN: 02703392) as Whole-time Director.

Terms of the re-appointments

• Mr. Sri Kalyan Kompella, who is also CFO: appointed on August 22, 2026 for five (5) consecutive years, from November 03, 2026 until November 02, 2031, subject to members' approval at the AGM. He has 25 plus years of experience in accounting, finance and administration.
• Dr. Sankaranarayanan Alangudi: appointed on August 22, 2026 for five (5) consecutive years, from January 06, 2027 until January 05, 2032, subject to members' approval. He is a discovery biologist and scientist with more than 45 years of experience in pharmaceutical R&D, with a track record in establishing drug discovery and development facilities and implementing GxP standards.
• Mr. Kalyan Ram Mangipudi: recorded as "No Change" since he retires by rotation and offered himself for re-appointment. He has 23 plus years of experience in accounting, finance and administration.
• No relationships between directors were applicable.

Voting process

Remote e-voting was open from 9:00 a.m. on September 27, 2026 to 5:00 p.m. on September 29, 2026, and e-voting was also available at the meeting via CDSL. Mr. G. Vinay, Practising Company Secretary, acted as Scrutinizer. The meeting concluded at 4:02 p.m., with the e-voting window kept open for a further 15 minutes. Voting results are to be sent to the stock exchanges and uploaded on the company's website and the CDSL platform on or before October 03, 2026.

How to read this

The update records continuity in the senior management team rather than any new appointment or exit. It also notes that the Auditors' Report carried no qualifications or observations, so it was not read out at the meeting. Members who registered as speakers raised questions, which directors answered. The outcome of the votes will be known from the separate voting results disclosure.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.